Skip to main content
. Author manuscript; available in PMC: 2015 Sep 22.
Published in final edited form as: Vaccine. 2011 Jul 13;29(36):6072–6078. doi: 10.1016/j.vaccine.2011.07.015

Table 1.

Key Issues raised during moderated audience discussion at AIDS Vaccine 2010 Satellite Symposium “Preparing for the Availability of a Partially Effective HIV Vaccine”, Atlanta GA, September 28, 2010.

  • Considerations for low and middle income countries:

    • 1.1

      Need help with algorithm for introduction of HIV biomedical interventions; need to start by identifying gaps in knowledge in each country/setting.

    • 1.2

      The lesson from hepatitis B vaccine that there was poor availability in countries at greatest need for decades; this was only solved by manufacturing in the region.

    • 1.3

      Access to licensed vaccines is still poor in many countries; what will be the impact of the current funding gap for Global Alliance on Vaccines and Immunizations (GAVI) and advanced market initiative on future HIV vaccines?

    • 1.4

      Adult vaccination programs need improving globally in each country.

    • 1.5

      Countries differ in their risk groups for HIV and the relative maturity of their national immunization program; probably won’t be single size fits all.

    • 1.6

      The health care workers are already overworked; therefore the logistics of a future HIV vaccine will be critical (e.g., multiple doses in high risk groups => low coverage)

    • 1.7

      Need to better translate meaning of “partial” efficacy for the general public

    • 1.8

      Consult community more with messaging on the results before dissemination

  • Considerations for high income countries:

    • 2.1

      Much practical/implementation resource already available in the routine immunization program.

    • 2.2

      Mostly an issue of competing priorities, especially if HIV prevalence/incidence is low.

    • 2.3

      Funding for childhood vaccines well established; adolescents/adults more challenging.

    • 2.4

      Need to think about incentives vs. removing barriers to immunizations.